MCID: THY025
MIFTS: 55

Thymus Cancer

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer 12 43 15
Malignant Neoplasm of Thymus 72 33
Thymus Neoplasms 44 72
Thymus Neoplasm 75 17
Thymic Tumor 12 59
Neoplasm of Thymus 12
Thymoma, Familial 72
Thymic Carcinoma 72
Thymic Neoplasms 55
Thymic Neoplasm 12
Thymoma, Type C 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3277
ICD9CM 35 164.0
MeSH 44 D013953
NCIt 50 C4962
SNOMED-CT 68 94096009
ICD10 33 C37
UMLS via Orphanet 73 C3714644
Orphanet 59 ORPHA100100
UMLS 72 C0205969 C0751552 C1322286 more

Summaries for Thymus Cancer

MedlinePlus : 43 The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary : Thymus Cancer, also known as malignant neoplasm of thymus, is related to thymic epithelial tumor and myasthenia gravis. An important gene associated with Thymus Cancer is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and T cell receptor signaling pathway. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include thymus, testes and lung, and related phenotypes are neoplasm of the thymus and dyspnea

Disease Ontology : 12 An immune system cancer located in the thymus.

Wikipedia : 75 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 147, show less)
# Related Disease Score Top Affiliating Genes
1 thymic epithelial tumor 30.8 KIT CD5
2 myasthenia gravis 30.8 TTN MUSK IL2 AIRE
3 teratoma 30.6 NKX2-1 KRT7 KIT
4 cavernous hemangioma 30.4 NKX2-1 KRT7 KIT
5 small cell cancer of the lung 29.9 NKX2-1 KRT7 KIT AKT1
6 thymus lipoma 29.0 KRT7 CD8A CD5 CD4 CD1B CD1A
7 thymoma 28.5 TTN THY1 PSMB11 NKX2-1 KIT IL2
8 thymic carcinoma 11.5
9 immunodeficiency with thymoma 11.4
10 ovarian germ cell teratoma 10.7 NKX2-1 KRT7
11 solid adenocarcinoma with mucin production 10.7 NKX2-1 KRT7
12 small cell carcinoma of the bladder 10.7 NKX2-1 KRT7
13 dendritic cell thymoma 10.7 TTN CD5
14 lung acinar adenocarcinoma 10.7 NKX2-1 KRT7
15 ovarian germ cell cancer 10.7 NKX2-1 KRT7
16 hemangioma of lung 10.6 NKX2-1 AKT1
17 papillary adenoma 10.6 NKX2-1 KRT7
18 metal allergy 10.6 CD8A CD4
19 ceruminoma 10.6 KRT7 KIT
20 jejunal cancer 10.6 KRT7 KIT
21 maxillary sinus adenoid cystic carcinoma 10.6 KIT IL2
22 intratubular embryonal carcinoma 10.5 KRT7 KIT
23 cribriform carcinoma 10.5 KRT7 KIT
24 mixed type thymoma 10.5 KIT CD5
25 polyclonal hypergammaglobulinemia 10.5 CD8A CD4
26 thymus adenocarcinoma 10.5 KRT7 CD5
27 lymphatic system disease 10.5 TTN IL2 CD5
28 adenoid basal cell carcinoma 10.5 KRT7 KIT
29 large cell neuroendocrine carcinoma 10.5 NKX2-1 KRT7 KIT
30 adenosquamous carcinoma 10.5 NKX2-1 KRT7 KIT
31 small cell carcinoma 10.5 NKX2-1 KRT7 KIT
32 merkel cell carcinoma 10.5 NKX2-1 KRT7 KIT
33 necrotizing sialometaplasia 10.4 KRT7 KIT CD5
34 ocular melanoma 10.4 KIT IL2
35 respiratory system disease 10.4 NKX2-1 IL2 AKT1
36 lymphoepithelioma-like thymic carcinoma 10.4 KIT CD5
37 thymoma, familial 10.4
38 gastrointestinal system cancer 10.4 KRT7 KIT AKT1
39 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 10.3 IL2 CD4 AIRE
40 malignant leydig cell tumor 10.3 KRT7 KIT
41 papillary serous adenocarcinoma 10.3 NKX2-1 KRT7
42 moderately-differentiated thymic neuroendocrine carcinoma 10.3
43 poorly differentiated thymic neuroendocrine carcinoma 10.3
44 thymoma type a 10.3
45 thymoma type b 10.3
46 thymoma type ab 10.3
47 well-differentiated thymic neuroendocrine carcinoma 10.3
48 thymic epithelial neoplasm 10.3
49 thymic neuroendocrine carcinoma 10.3
50 lung adenoid cystic carcinoma 10.3 NKX2-1 KIT
51 leukocyte disease 10.2 KIT IL2 CD5 AKT1
52 renal cell carcinoma, nonpapillary 10.1 NKX2-1 KRT7 KIT IL2
53 gastrointestinal system disease 10.1 KIT IL2 AKT1
54 bladder lymphoma 10.1 KRT7 CD5
55 paraneoplastic syndromes 10.0
56 lymphoma 10.0
57 mycobacterium malmoense 9.9 CD1E CD1B CD1A
58 warthin tumor 9.9 THY1 KRT7 KIT
59 adenoid cystic carcinoma 9.9
60 thymus lymphoma 9.9
61 hemopericardium 9.9
62 pericardial effusion 9.9
63 esophagitis 9.9
64 neutropenia 9.9
65 agammaglobulinemia 9.9
66 rare tumor 9.9
67 murray valley encephalitis 9.8 THY1 IL2
68 neuroendocrine carcinoma 9.8
69 periostitis 9.8
70 myasthenia gravis congenital 9.8
71 multiple endocrine neoplasia 9.8
72 acanthosis nigricans 9.8
73 lymphoma, hodgkin, classic 9.8
74 panbronchiolitis, diffuse 9.8
75 aplastic anemia 9.8
76 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
77 good syndrome 9.8
78 lymphoblastic lymphoma 9.8
79 castleman disease 9.8
80 goiter 9.8
81 pure red-cell aplasia 9.8
82 neuroendocrine tumor 9.8
83 gangliocytoma 9.8
84 hemangioma 9.8
85 adenocarcinoma 9.8
86 neurilemmoma 9.8
87 germinoma 9.8
88 seminoma 9.8
89 large cell carcinoma 9.8
90 ganglioneuroma 9.8
91 mediastinal cancer 9.8
92 lymphoepithelioma-like carcinoma 9.8
93 cortical thymoma 9.8
94 epithelial malignant thymoma 9.8
95 bronchiectasis 9.8
96 carcinoma showing thymus-like differentiation 9.8
97 thymic neuroendocrine tumor 9.8
98 red cell aplasia 9.8
99 polyneuropathy 9.7
100 paraneoplastic polyneuropathy 9.7
101 autoimmune disease 9.7
102 multiple endocrine neoplasia, type i 9.7
103 lymphoma, mucosa-associated lymphoid type 9.7
104 thyroid carcinoma, familial medullary 9.7
105 lung cancer 9.7
106 testicular germ cell tumor 9.7
107 kearns-sayre syndrome 9.7
108 gastrointestinal stromal tumor 9.7
109 myocardial infarction 9.7
110 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
111 membranous nephropathy 9.7
112 deficiency anemia 9.7
113 infective endocarditis 9.7
114 cholelithiasis 9.7
115 dermatomyositis 9.7
116 endocarditis 9.7
117 lymphocytic leukemia 9.7
118 lipoid nephrosis 9.7
119 leukemia 9.7
120 crescentic glomerulonephritis 9.7
121 pleural disease 9.7
122 leiomyosarcoma 9.7
123 benign mesothelioma 9.7
124 glomerulonephritis 9.7
125 spindle cell thymoma 9.7
126 mesenchymal cell neoplasm 9.7
127 liposarcoma 9.7
128 thyroid gland medullary carcinoma 9.7
129 myopathy 9.7
130 histiocytoma 9.7
131 type c thymoma 9.7
132 rapidly progressive glomerulonephritis 9.7
133 testicular germ cell cancer 9.7
134 predominantly cortical thymoma 9.7
135 b-cell lymphoma 9.7
136 vasculitis 9.7
137 neurofibroma 9.7
138 anca-associated vasculitis 9.7
139 aortopulmonary window 9.7
140 germ cells tumors 9.7
141 microscopic polyangiitis 9.7
142 differentiated thyroid carcinoma 9.7
143 virus-associated trichodysplasia spinulosa 9.7
144 primary mediastinal large b-cell lymphoma 9.7
145 thyroid carcinoma 9.7
146 immune system organ benign neoplasm 9.5 KRT7 CD8A CD5 CD4 CD1B CD1A
147 thymus gland disease 7.4 TTN TSR1 PSMB11 MUSK KIT KCNA4

Graphical network of the top 20 diseases related to Thymus Cancer:



Diseases related to Thymus Cancer

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

59 32 (showing 21, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the thymus 59 32 hallmark (90%) Very frequent (99-80%) HP:0100521
2 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
3 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
4 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
5 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
6 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
7 mediastinal lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0100721
8 diaphragmatic paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0006597
9 dysgammaglobulinemia 59 32 frequent (33%) Frequent (79-30%) HP:0002961
10 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
11 dysphagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002015
12 increased intracranial pressure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002516
13 abnormal bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0001892
14 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
15 autoimmunity 59 32 occasional (7.5%) Occasional (29-5%) HP:0002960
16 neuroendocrine neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0100634
17 headache 59 32 occasional (7.5%) Occasional (29-5%) HP:0002315
18 fatigable weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003473
19 cardiac arrest 59 32 occasional (7.5%) Occasional (29-5%) HP:0001695
20 language impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002463
21 edema 59 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymus Cancer:

46 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.03 AIRE AKT1 CD4 CD5 CD8A CNTNAP2
2 behavior/neurological MP:0005386 10.02 AIRE AKT1 CNTNAP2 DPYSL5 IL2 KCNA4
3 no phenotypic analysis MP:0003012 9.7 AIRE CD4 CD5 IL2 KIT NKX2-1
4 normal MP:0002873 9.61 AIRE AKT1 CD4 CD5 CD8A KIT
5 respiratory system MP:0005388 9.17 AIRE AKT1 IL2 KIT MUSK NKX2-1

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 125, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Analgesics Phase 3
4 Peripheral Nervous System Agents Phase 3
5 Liver Extracts Phase 3
6 Cola Phase 3
7 Anesthetics, Intravenous Phase 3
8 Narcotics Phase 3
9 Analgesics, Opioid Phase 3
10 Adjuvants, Anesthesia Phase 3
11 Central Nervous System Depressants Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics Phase 3
14
Bevacizumab Approved, Investigational Phase 2 216974-75-3
15
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
16
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
17
Pasireotide Approved Phase 2 396091-73-9 9941444
18
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
21
Melphalan Approved Phase 2 148-82-3 460612 4053
22
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
23
Busulfan Approved, Investigational Phase 2 55-98-1 2478
24
Rabeprazole Approved, Investigational Phase 1, Phase 2 117976-89-3 5029
25
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
26
nivolumab Approved Phase 2 946414-94-4
27
Nedaplatin Approved, Investigational Phase 2 95734-82-0
28
Ramucirumab Approved, Investigational Phase 2 947687-13-0
29
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
30
Durvalumab Approved, Investigational Phase 2 1428935-60-7
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
33
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
34
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
35
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Coal tar Approved Phase 1, Phase 2 8007-45-2
38
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
39
Pembrolizumab Approved Phase 2 1374853-91-4
40
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
41
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
42
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
45
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
46
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
47
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
48
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
49 Amrubicin Investigational Phase 2 110267-81-7
50
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
51
Lexatumumab Investigational Phase 2 845816-02-6
52
Tremelimumab Investigational Phase 2 745013-59-6
53
Saracatinib Investigational Phase 2 379231-04-6
54
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
55
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
56 Hormone Antagonists Phase 2
57 glucocorticoids Phase 2
58 Gastrointestinal Agents Phase 2
59 Antineoplastic Agents, Hormonal Phase 2
60 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
61 Prednisolone acetate Phase 2
62 Neuroprotective Agents Phase 2
63 Antiemetics Phase 2
64 Antilymphocyte Serum Phase 2
65 Methylprednisolone Acetate Phase 2
66 Protective Agents Phase 2
67 Cyclosporins Phase 2
68 Dermatologic Agents Phase 2
69 Calcineurin Inhibitors Phase 2
70 Autonomic Agents Phase 2
71 Antacids Phase 1, Phase 2
72 Proton Pump Inhibitors Phase 1, Phase 2
73 Anti-Ulcer Agents Phase 1, Phase 2
74 Antibodies, Monoclonal Phase 2
75 Nucleic Acid Synthesis Inhibitors Phase 1, Phase 2
76 Hormones Phase 1, Phase 2
77 Calcium, Dietary Phase 1, Phase 2
78 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
79 Etoposide phosphate Phase 2
80 Angiogenesis Inhibitors Phase 2
81 Angiogenesis Modulating Agents Phase 2
82 Antibodies Phase 1, Phase 2
83 Immunoglobulins Phase 1, Phase 2
84 Antifungal Agents Phase 2
85 Immunotoxins Phase 1, Phase 2
86 Antineoplastic Agents, Immunological Phase 2
87 Protein Kinase Inhibitors Phase 2
88 Anti-Inflammatory Agents Phase 1, Phase 2
89 Cyclooxygenase Inhibitors Phase 1, Phase 2
90 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
91 Vaccines Phase 1, Phase 2
92 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
93 Analgesics, Non-Narcotic Phase 1, Phase 2
94 Tubulin Modulators Phase 2
95 Albumin-Bound Paclitaxel Phase 2
96 Antimitotic Agents Phase 2
97 Topoisomerase Inhibitors Phase 1, Phase 2
98 Immunologic Factors Phase 1, Phase 2
99 Histone Deacetylase Inhibitors Phase 1, Phase 2
100 Anti-Bacterial Agents Phase 1, Phase 2
101 Immunosuppressive Agents Phase 1, Phase 2
102 Antibiotics, Antitubercular Phase 1, Phase 2
103 Alkylating Agents Phase 1, Phase 2
104 Antirheumatic Agents Phase 1, Phase 2
105 Antineoplastic Agents, Alkylating Phase 1, Phase 2
106
Liposomal doxorubicin Phase 1, Phase 2 31703
107
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 60843 446556
108
leucovorin Approved Phase 1 58-05-9 143 6006
109
Gemcitabine Approved Phase 1 95058-81-4 60750
110
Pancrelipase Approved, Investigational Phase 1 53608-75-6
111
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
112
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
113 Interferon-beta Phase 1
114 interferons Phase 1
115 Imatinib Mesylate Phase 1 220127-57-1 123596
116 Folic Acid Antagonists Phase 1
117 Vitamin B9 Phase 1
118 Folate Phase 1
119 Vitamin B Complex Phase 1
120 Immunoconjugates Phase 1
121 pancreatin Phase 1
122 Maytansine Phase 1
123 Antimetabolites Phase 1
124 Antimetabolites, Antineoplastic Phase 1
125
Parathyroid hormone Approved, Investigational 9002-64-6

Interventional clinical trials:

(showing 84, show less)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
4 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
5 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Unknown status NCT02607631 Phase 2 Pembrolizumab
6 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
7 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
8 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
9 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
10 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
11 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
12 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
13 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
14 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
15 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
16 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
17 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
18 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
19 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
20 An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours Completed NCT01283945 Phase 1, Phase 2 Lucitanib
21 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
22 Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Completed NCT01624090 Phase 2 Mithramycin
23 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
24 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
25 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
26 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
27 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
28 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
29 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Recruiting NCT03466827 Phase 2 Selinexor
30 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
31 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting NCT01325441 Phase 1, Phase 2 BBI608;Paclitaxel
32 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
33 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
34 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
35 A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors Recruiting NCT02938793 Phase 2 Durvalumab;Tremelimumab
36 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
37 Phase Ⅱ Study of Concurrent Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors Active, not recruiting NCT02636556 Phase 2
38 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
39 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
40 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
41 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Active, not recruiting NCT02307500 Phase 2 Regorafenib
42 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Active, not recruiting NCT02220855 Phase 2 BKM120
43 A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
44 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Not yet recruiting NCT03858582 Phase 2 pembrolizumab
45 Samsung Medical Center Not yet recruiting NCT03219554 Phase 2 Palbociclib
46 Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Suspended NCT02054104 Phase 1, Phase 2 Cyclophosphamide;Celecoxib
47 A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
48 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib
49 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
50 Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated NCT01301391 Phase 2 Milciclib Maleate
51 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy Terminated NCT01011439 Phase 2 Milciclib Maleate
52 A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors Withdrawn NCT01610544 Phase 2 3'-deoxy-3'-18F fluorothymidine (FLT)
53 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Unknown status NCT00066404 Phase 1
54 Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
55 Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury Completed NCT00921739 Phase 1
56 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
57 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
58 Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Recruiting NCT03023319 Phase 1 Bosutinib;Pemetrexed
59 Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
60 Phase I Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies Active, not recruiting NCT01165658 Phase 1
61 Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas Terminated NCT01258868 Phase 1 Celebrex
62 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
63 Preoperative Prediction of the Pathological Classification of Thymic Epithelial Tumors by Apparent Diffusion Coefficient Using Ultra-high B-values Unknown status NCT03212027
64 Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment Unknown status NCT00372840
65 Evaluate the Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors Completed NCT03288662
66 Prospective Ⅱ Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699
67 Biological Analysis of a Series of Thymoma and Thymic Carcinoma: Genetic Aberrations and Potential Therapy Targets. Completed NCT00965627
68 Characteristics of Patients With Thymoma Undergone Thymectomy in Chulalongkorn Hospital Between 2003-2007 Completed NCT01123590
69 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
70 The Role of the Thymus in Myasthenia Gravis Completed NCT01102192
71 Preoperative Oncogeriatric Assessment for Thoracic Malignancies Completed NCT00591981
72 A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers Completed NCT01794676
73 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors Completed NCT02233842
74 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
75 French National Observatory of Patients With Thymic Epithelial Tumor Recruiting NCT02724696
76 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers Recruiting NCT01950572
77 A Prospective Multicenter Comparative Study of the Curative Effect of Extended Thymectomy Performed Through the Subxiphoid VATS Approach With Double Elevation of the Sternum Versus Intercostal VATS Approach Recruiting NCT03613272
78 Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors Recruiting NCT02146170
79 Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, and Patients Treated With an Adoptive Cellular Therapy Recruiting NCT01851395
80 Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies Recruiting NCT00242723
81 Can MRI Replace CT in the Evaluation of Thymoma? Active, not recruiting NCT03968315
82 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722
83 The Master Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Treatment: CAR-T
84 Study on Regulation of LncRNA to Regulatory B Cells(Bregs) Through Notch Pathway in Patients With Thymoma and Autoimmune Diseases Withdrawn NCT02948855

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Genetic Tests for Thymus Cancer

Anatomical Context for Thymus Cancer

MalaCards organs/tissues related to Thymus Cancer:

41
Thymus, Testes, Lung, Bone, Liver, B Cells, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Thymus Cancer:

19
Thymus

Publications for Thymus Cancer

Articles related to Thymus Cancer:

(showing 42, show less)
# Title Authors PMID Year
1
A "coughed up" tissue diagnosed as type A thymoma in an 80-year-old man: A case report. 17
31277185 2019
2
Invasive thymoma leading to pulmonary artery embolism during operation: A case report. 17
31305442 2019
3
Surgical Decision Making: Thymoma and Myasthenia Gravis. 17
30928002 2019
4
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). 38
29660598 2018
5
Thymic Carcinoma Associated with Cerebellar Degeneration. 38
30756016 2018
6
Diagnosis of Churg-Strauss Syndrome Presented With Neuroendocrine Carcinoma: A Case Report. 38
28758089 2017
7
Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. 38
27197189 2016
8
[The anti-tumor mechanisms in long-lived rodents]. 38
27232489 2016
9
Sunitinib effective for rare thymus cancer. 38
25680712 2015
10
Gene mutation may signal indolent thymus cancer. 38
25185203 2014
11
Excessive risk of cancer and in particular lymphoid malignancy in myasthenia gravis patients: a population-based cohort study. 38
24332676 2014
12
Six cases report of differential diagnosis of periapical diseases. 38
21789964 2011
13
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 38
18647207 2009
14
Limited upper sternotomy in general thoracic surgery. 38
18368317 2008
15
Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. 9
12777991 2003
16
[Prevalence of the neuroendocrine phenotype in thymus neoplasms]. 38
12192931 2002
17
Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. 9
11952859 2002
18
[The importance of magnetic resonance tomography in the detection of a thymus cancer. A case report]. 38
8303472 1993
19
[The diagnostic and treatment characteristics of myasthenia in thymus neoplasms]. 38
8329236 1993
20
Thymus cancer epidemiology in England and Wales. 38
2372494 1990
21
[Thymus neoplasms with myasthenic syndrome]. 38
6865224 1983
22
[Cytological changes in the tumor, bone marrow and leukoconcentrate of peripheral blood in thymus neoplasms]. 38
331673 1977
23
[Pathological anatomy of thymus neoplasms]. 38
1029800 1976
24
[Cushing's syndrome in thymus neoplasms structurally resembling carcinoid tumor]. 38
1208153 1975
25
[Problems of thymus neoplasms. Introductory remarks]. 38
1118302 1975
26
[Thymus neoplasms. Opening remarks]. 38
235118 1975
27
[Thymus neoplasms associated with myasthenia gravis]. 38
1118308 1975
28
[Morphological and biological particuliarities of thymus neoplasms]. 38
4603689 1974
29
[Thymus neoplasms. Clinical aspects, therapy and prognosis]. 38
4589046 1973
30
[Therapy of thymus neoplasms and of myasthenia gravis pseudoparalytica]. 38
4782941 1973
31
[Thymus neoplasms in children]. 38
4740635 1973
32
[On several cases of thymus neoplasms with a benign course]. 38
4791573 1973
33
[Myasthenia and thymus neoplasms]. 38
5020029 1972
34
[Thymus neoplasms]. 38
4678742 1972
35
[Acute mediastinal syndrome caused by malignant thymus neoplasms in children]. 38
5533435 1970
36
[Thymus neoplasms: clinical, pathological and radiological study on 40 patients]. 38
5442800 1970
37
[Cytocaryological study on thymus neoplasms]. 38
5526168 1970
38
[Paraneoplastic polyneuropathy in thymus cancer]. 38
5811275 1969
39
[Problems in the clinical diagnosis of thymus neoplasms]. 38
5637541 1968
40
[Thymus neoplasms in childhood]. 38
5759013 1968
41
[Myasthenia gravis in thymus neoplasms]. 38
5175158 1964
42
[The thymus & cancer]. 38
13524076 1958

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

9 (showing 9, show less)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44380 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 30
2 COSM14140 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 30
3 COSM6191487 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 30
4 COSM6191489 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 30
5 COSM2006821 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.11824C>T p.R3942W 12:49032071-49032071 30
6 COSM133763 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 30
7 COSM6191682 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 30
8 COSM6196604 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 30
9 COSM6191486 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 30

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Pathways for Thymus Cancer

GO Terms for Thymus Cancer

Cellular components related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 5, show less)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.61 THY1 MUSK KIT KCNA4 CD8A CD5
2 external side of plasma membrane GO:0009897 9.55 THY1 KIT CD8A CD5 CD4
3 T cell receptor complex GO:0042101 9.32 CD8A CD4
4 axolemma GO:0030673 9.26 THY1 CNTNAP2
5 cell surface GO:0009986 9.02 THY1 KIT CNTNAP2 CD4 CD1B

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 13, show less)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 IL2 CD8A CD4 CD1E CD1B CD1A
2 positive regulation of gene expression GO:0010628 9.89 TTN NKX2-1 MUSK KIT AKT1
3 cytokine-mediated signaling pathway GO:0019221 9.83 KIT IL2 CD4 AKT1
4 positive regulation of protein phosphorylation GO:0001934 9.78 MUSK IL2 CD4 AKT1
5 adaptive immune response GO:0002250 9.77 IL2 CD4 CD1E CD1B CD1A
6 protein autophosphorylation GO:0046777 9.76 THY1 MUSK KIT AKT1
7 immune response GO:0006955 9.7 IL2 CD8A CD4 CD1E CD1B CD1A
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 MUSK KIT CD8A CD4
9 T cell differentiation GO:0030217 9.58 KIT IL2 CD4
10 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.51 CD4 AKT1
11 positive regulation of T cell mediated cytotoxicity GO:0001916 9.43 CD1E CD1B CD1A
12 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.13 CD1E CD1B CD1A
13 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 8.8 CD1E CD1B CD1A

Molecular functions related to Thymus Cancer according to GeneCards Suite gene sharing:

(showing 7, show less)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 TTN THY1 CD8A CD4 AKT1
2 enzyme binding GO:0019899 9.73 TTN THY1 NKX2-1 CNTNAP2 CD4 AKT1
3 transmembrane signaling receptor activity GO:0004888 9.37 CD5 CD4
4 lipopeptide binding GO:0071723 9.33 CD1E CD1B CD1A
5 exogenous lipid antigen binding GO:0030884 9.13 CD1E CD1B CD1A
6 endogenous lipid antigen binding GO:0030883 8.8 CD1E CD1B CD1A
7 protein binding GO:0005515 10.25 TTN THY1 NKX2-1 MUSK KRT7 KIT

Sources for Thymus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....